Scientific Achievement is in our DNA ...  Supporting World-Class Cancer Research in Israel ...  Scientific Achievement is in our DNA ... Supporting World-Class Cancer Research in Israel ...  Scientific Achievement is in our DNA ...  Supporting World-Class Cancer Research in Israel ... Scientific Achievement is in our DNA ...  Supporting World-Class Cancer Research in Israel ...Scientific Achievement is in our DNA ...  Supporting World-Class Cancer Research in Israel ... Scientific Achievement is in our DNA ...  Supporting World-Class Cancer Research in Israel ... Scientific Achievement is in our DNA ... Supporting World-Class Cancer Research in Israel ...  Scientific Achievement is in our DNA ...  Supporting World-Class Cancer Research in Israel ... Scientific Achievement is in our DNA ...  Supporting World-Class Cancer Research in Israel ... Scientific Achievement is in our DNA ...  Supporting World-Class Cancer Research in Israel ... Scientific Achievement is in our DNA ... Supporting World-Class Cancer Research in Israel ...

Our Impact on Cancer

ICRF is proud to note that many of its awardees have been and continue to be involved with major cancer research breakthroughs:

Velcade - a drug used to treat multiple myeloma, a cancer of the bone marrow, was developed based on the research of ICRF Professors and Nobel Prize winners, Drs. Avram Hershko and Aaron Ciechanover, Technion,
                                              Israel Institute of Technology.

Gleevec - the first drug to directly target cancer cells, was developed based on the research work of ICRF awardee, Dr. Eli Canaani, Weizmann Institute of Science.

 

Doxil - the first drug encapsulated in a liposome (or microscopic fat bubble) for direct delivery to a tumor site, was developed by ICRF awardee, Dr. Alberto Gabizon, Shaare Zedek Medical Center.
 

The p53 Gene - originally thought to cause cancer, was correctly identified as a tumor suppressor, and its role in the majority of human cancers further elucidated by ICRF awardees, Drs. Moshe Oren and Varda Rotter, Weizmann Institute of Science.

DNA Methylation - is a molecular process that turns genes on and off. Pioneering work in this area was performed by ICRF Professor and Israel Prize winner, Dr. Howard Cedar, Hebrew University/Hadassah Medical School.

 • The RAD51 Gene - The discovery that a minor mutation in this gene increases the risk of breast cancer in women with the BRCA2 gene mutation was made by ICRF awardee Dr. Ephrat Levy-Lahad, Shaare Zedek Medical Center.

A Novel Bone Marrow Transplant Technique - to greatly expand the donor pool for leukemia treatment, was developed by ICRF awardee,Dr.Yair Reisner,Weizmann Institute of Science.